{"nctId":"NCT01556997","briefTitle":"Perindopril Amlodipine for the Treatment of Hypertension","startDateStruct":{"date":"2012-02"},"conditions":["Essential Hypertension"],"count":837,"armGroups":[{"label":"XOMA 985","type":"EXPERIMENTAL","interventionNames":["Drug: XOMA 985"]},{"label":"Amlodipine Besylate (AMLb)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Amlodipine Besylate"]},{"label":"Perindopril Erbumine (PERe)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Perindopril Erbumine"]}],"interventions":[{"name":"XOMA 985","otherNames":[]},{"name":"Amlodipine Besylate","otherNames":[]},{"name":"Perindopril Erbumine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Essential hypertension\n* For female subjects, a negative serum pregnancy test\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Night shift workers whose work hours include midnight to 4:00 a.m.\n* Secondary hypertension\n* An arm size that precludes the use of the digital blood pressure monitor cuff (arm size \\> 42 cm)\n* Renal dysfunction, severe renal impairment, bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, subjects with only 1 kidney, or post-renal transplant subjects\n* Female subjects who are pregnant, planning to become pregnant\n* History of malignancy within 5 years\n* Primary aldosteronism\n* Heart failure (NYHA functional class 3-4), hypertrophic obstructive cardiomyopathy, or hemodynamically relevant stenosis of the aortic or mitral valve\n* Significant cardiac arrhythmias, MI, stroke, CABG, PTCA, unstable angina\n* Known hypersensitivity to any component of the study drugs\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Diastolic Blood Pressure (DBP).","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.7","spread":"8.38"},{"groupId":"OG001","value":"-13.2","spread":"8.33"},{"groupId":"OG002","value":"-9.5","spread":"8.77"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Systolic Blood Pressure (SBP).","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.4","spread":"13.86"},{"groupId":"OG001","value":"-19.6","spread":"15.62"},{"groupId":"OG002","value":"-13.4","spread":"14.66"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":279},"commonTop":["Edema peripheral","Headache","Cough","Dizziness","Fatigue"]}}}